Peng Xing-Jie, Hei Gang-Rui, Li Ran-Ran, Yang Ye, Liu Chen-Chen, Xiao Jing-Mei, Long Yu-Jun, Shao Ping, Huang Jing, Zhao Jing-Ping, Wu Ren-Rong
Mental Health Institute of the Second Xiangya Hospital, China National Clinical Research Center on Mental Disorders, China National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Central South University, Changsha, China.
Brain Hospital of Hunan Province, Changsha, China.
Front Hum Neurosci. 2021 Feb 22;14:599720. doi: 10.3389/fnhum.2020.599720. eCollection 2020.
: Cognitive impairment is one of the core symptoms of schizophrenia, which is considered to be significantly correlated to prognosis. In recent years, many studies have suggested that metabolic disorders could be related to a higher risk of cognitive defects in a general setting. However, there has been limited evidence on the association between metabolism and cognitive function in patients with early-stage schizophrenia. : In this study, we recruited 172 patients with early-stage schizophrenia. Relevant metabolic parameters were examined and cognitive function was evaluated by using the MATRICS Consensus Cognitive Battery (MCCB) to investigate the relationship between metabolic disorder and cognitive impairment. : Generally, the prevalence of cognitive impairment among patients in our study was 84.7% (144/170), which was much higher than that in the general population. Compared with the general Chinese setting, the study population presented a higher proportion of metabolic disturbance. Patients who had metabolic disturbance showed no significant differences on cognitive function compared with the other patients. Correlation analysis showed that metabolic status was significantly correlated with cognitive function as assessed by the cognitive domain scores ( < 0.05), while such association was not found in further multiple regression analysis. : Therefore, there may be no association between metabolic disorder and cognitive impairment in patients with early-stage schizophrenia. : Clinicaltrials.gov, NCT03451734. Registered March 2, 2018 (retrospectively registered).
认知障碍是精神分裂症的核心症状之一,被认为与预后显著相关。近年来,许多研究表明,在一般情况下,代谢紊乱可能与认知缺陷的较高风险有关。然而,关于早期精神分裂症患者代谢与认知功能之间关联的证据有限。
在本研究中,我们招募了172例早期精神分裂症患者。检测相关代谢参数,并使用MATRICS共识认知成套测验(MCCB)评估认知功能,以研究代谢紊乱与认知障碍之间的关系。
总体而言,我们研究中患者的认知障碍患病率为84.7%(144/170),远高于一般人群。与中国一般情况相比,研究人群中代谢紊乱的比例更高。有代谢紊乱的患者与其他患者在认知功能上无显著差异。相关分析表明,代谢状态与认知领域评分所评估的认知功能显著相关(<0.05),而在进一步的多元回归分析中未发现这种关联。
因此,早期精神分裂症患者的代谢紊乱与认知障碍之间可能没有关联。
Clinicaltrials.gov,NCT03451734。2018年3月2日注册(追溯注册)。